1. Apoptosis Cell Cycle/DNA Damage
  2. Apoptosis CDK Caspase Bcl-2 Family
  3. Metuzumab

Metuzumab  (Synonyms: Licartin; Metuximab; Mehuzumab)

目录号: HY-P991883
一键复制产品信息
技术支持

Metuzumab (Licartin) 是一种抗 CD147 人鼠嵌合 IgG1 单克隆抗体。Metuzumab 可诱导细胞凋亡 (Apoptosis),降低 Cyclin D1、全长 Caspase-3Bcl-2 水平,增加 Bax 水平。Metuzumab 可提高非小细胞肺癌 (NSCLC) 细胞对 Gemcitabine (HY-17026) 的敏感性。Metuzumab 可用于肝癌和非小细胞肺癌的研究 [1] [2]

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Metuzumab

Metuzumab Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].

反应种属

Human

IC50 & Target

Caspase-3

 

Bcl-2

 

Bax

 

体外研究
(In Vitro)

Metuzumab (0.1-100 μg/ml;48 h) 以剂量依赖性方式抑制二维培养中 SMMC-7721 细胞的迁移 [1]
Metuzumab (0.1-100 μg/ml;24 h) 在 2D Transwell 实验中以剂量依赖方式抑制 SMMC-7721 细胞的侵袭 [1]
Metuzumab (0.1-100 μg/ml;48 h) 以剂量依赖方式抑制 2D、3DP 和 3DPF 模型中 SMMC-7721 细胞的增殖 [1]
Metuzumab (24 h) 与 Gemcitabine 联用可诱导 A549、NCI-H460 和 NCI-H520 非小细胞肺癌 (NSCLC) 细胞发生 G1 期阻滞,并下调 cyclin D1[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay[1]

Cell Line: human hepatocellular carcinoma SMMC-7721 cells (2D model)
Concentration: 0.1-100 μg/ml
Incubation Time: 48 h
Result: Decreased migration distance with increasing dose; distances for 1, 10, 100 μg/ml groups were 126.1 ± 6.7 μm, 98.8 ± 2.4 μm, 73.3 ± 8.5 μm, respectively, all significantly shorter than negative control and 0.1 μg/ml groups
体内研究
(In Vivo)

Metuzumab (10 mg/kg,每周两次) 可在 BALB/c 无胸腺裸鼠 NSCLC 异种移植模型中抑制 NSCLC 肿瘤生长并增强 GP 化疗的疗效 (肿瘤生长抑制率最高达 91.89%) [2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c athymic nude mice (female, 5–6 weeks old)[2]
Dosage: 10 mg/kg
Administration: twice weekly
Result: Reduced tumor volume by 39.34% (A549), 36.39% (NCI-H460), and 35.18% (NCI-H520) compared to saline controls. Enhanced tumor growth inhibition to 91.89% (A549, p < 0.001 vs. GP alone), 73.99% (NCI-H460, p = 0.0001 vs. GP alone), and 69.74% (NCI-H520, p < 0.001 vs. GP alone) when combined with GP. Increased deoxycytidine kinase (dCK) expression by 2.1-fold (A549), 1.4-fold (NCI-H460), and 1.7-fold (NCI-H520) in tumor tissues (measured by IOD).
基因 ID

682  [NCBI]

Accession
应用

ELISA, FACS, Functional assay

偶联物

Unconjugated

复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Metuzumab
目录号:
HY-P991883
需求量: